On January 15 2016, reports from two early-stage trials of new oral drugs provide hope for patients with high-risk chronic lymphocytic leukemia (CLL) that has returned after prior treatment. Read more here.
Studies mentioned in article:
Byrd J. C., Harrington B., O'Brien S., (2016). Acalabrutinib (ACP-196) in relapsed chronic lymphocytic leukemia. New England Journal of Medicine, 374, 323-332.
Roberts A. W., Davids M. S., Pagel J. M., (2016). Targeting BCL2 with venetoclax in relapsed chronic lymphocytic leukemia. New England Journal of Medicine, 374, 311-322.
No comments:
Post a Comment